| Neurogastroenterol Motil. 2010 Mar;22(3):285-e81. Epub 2009 Dec 22. Serum correlates of the placebo effect in irritable bowel syndrome. Kokkotou E, Conboy LA, Ziogas DC, Quilty MT, Kelley JM, Davis RB, Lembo AJ, Kaptchuk TJ. |
This study followed Conboy et al (2009) (see below) The new study involved testing a panel of 10 serum biomarkers at enrolment and at the third week of intervention. Patients who received placebo treatment showed more changes over time in serum levels of osteoprotegerin (OPG) compared with the waitlist group. In addition, serum levels of OPG at baseline were found to be higher in patients who subsequently achieved adequate relief (AR) of IBS symptoms, irrespective of their treatment group. Serum levels of another protein called TWEAK (TNF-related weak inducer of apoptosis) were also higher at baseline in patients who reported AR and in particular in those who reported AR with placebo treatment. The authors conclude that knowledge of such predictors of the placebo response could improve the design of clinical trials. |
|
Gastroenterol Nurs. 2009 Jul-Aug;32(4):243-55.
|
After 4 weeks of twice-weekly Acu/Moxa treatment, average daily abdominal pain/discomfort improved whereas the control group showed minimal reduction. This between-group difference adjusted for baseline difference was statistically significant. The intestinal gas, bloating, and stool consistency composite score showed a similar pattern of improvement. The findings indicate that Acu/Moxa treatment shows promise in the area of symptom management for IBS.
|
|
Am J Gastroenterol. 2009 Jun;104(6):1489-97. |
In this study both traditional acupuncture and sham acupuncture groups improved significantly compared with the waitlist control group. (see Conboy et al 2010 follow up study, above) |